Shockwave Medical Reports Turnaround Q4 Profit On 270% Sales Growth; Guides Above Consensus

Shockwave Medical Inc's SWAV fourth-quarter FY21 sales were up 271% Y/Y to $84.2 million, beating the consensus of $75.43 million.

  • The revenue growth was primarily driven by the launch of the coronary product, Shockwave C2, sales force expansion in the U.S., and increased penetration in both U.S. & international markets.
  • Gross margin improved to 85% from 72% due to product mix and continued improvement in manufacturing productivity & process efficiencies.
  • Cash, cash equivalents, and short-term investments totaled $201 million.
  • Related: Penumbra Weighs Combination With Shockwave Medical: Bloomberg.
  • Centers for Medicare & Medicaid Services reassigned the payment for peripheral IVL procedures performed above the knee arteries in the hospital outpatient setting, thereby increasing the payments hospitals receive for these procedures.
  • The Company posted EPS of $0.34, a turnaround from EPS loss of $(0.46), surpassing the analyst consensus estimate of $0.08.
  • Guidance: Shockwave Medical expects FY22 sales of $405 million - $425 million, up 71% -79%, higher than the consensus of $386.73 million.
  • Price Action: SWAV shares closed 8.60% higher at $155.15 during after-hours trading on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!